Cancer is a leading cause of death for children and adolescents worldwide. Brain tumors are among the most common childhood cancers and one of the most difficult to treat (WHO fact sheet 2018). Neoantigens are the future of personalized cancer vaccines and expected to be key markers for prediction of response to immune checkpoint blockers (Finotello et al. 2019). For an enhanced prediction of neoantigens, we are planning to integrate new alignment-free approach for fusion gene detection and variant phasing into the most recent version of pVAC toolkit for neoantigen detection (Hundal et al. 2018).
What are the goals of this project?
Our project aims for the identification of novel neoantigens for immunotherapy in pediatric brain tumors to help achieving improved outcomes.
What is the impact of this project?
Identification of neoantignes in those patients should enable the development of new immunotherapies to help treat and improve the outcome of similar patients
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.